Related Experiment Videos
New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy
I Virgolini1, T Traub, M Leimer
1Department of Nuclear Medicine, University of Vienna, Austria.
Abstract:
In vitro data have demonstrated a high amount of receptors for various hormones and peptides on malignant cells of neuroendocrine origin. Among these, binding sites for members of the SST-family (hSSTR1-5) are frequently found, and their expression has led to therapeutic and diagnostic attempts to specifically target these receptors. Receptor scintigraphy using radiolabeled peptide ligands has proven its effectiveness in clinical practice. In addition, initial results have indicated a clinical potential for receptor-targeted radiotherapy. Based on somatostatin (SST) receptor (R) recognition, the novel radiopharmaceuticals 111In/90Y-DOTA-lanreotide developed at the University of Vienna as well as 111In/90Y-DOTA-DPhe1-Tyr3-octreotide (NOVARTIS) both have provided promising data for diagnosis and treatment of hSSTR-positive tumors. SSTR scintigraphy using 111In-DTPA-DPhe1-octreotide has a high positive predictive value for the vast majority of neuroendocrine tumors and has gained its place in the diagnostic work-up as well as follow-up of patients. We have used 111In-DOTA-lanreotide scintigraphy in 166 patients since 1997 and have seen positive results in 93% of patients. In 42 patients with neuroendocrine tumors comparative data were obtained. As opposed to 111In-DTPA-DPhe1-octreotide and 111In-DOTA-DPhe1-Tyr3-octreotide, discrepancies in the scintigraphic results were seen in about one third of patients concerning both the tumor uptake as well as tumor lesion detection. Initial results both with 90Y-DOTA-lanreotide as well as 90Y-DOTA-DPhe1-Tyr3-octreotide has pointed out the clinical potential of radionuclide receptor-targeted radiotherapy. This new therapy could offer palliation and disease control at a reduced cost. The final peptide therapy strategy is most probably cheaper than conventional radiotherapies or prolonged chemotherapies. Overall, receptor-mediated radiotherapy with 90Y-DOTA-lanreotide/90Y-DOTA-DPhe1-Tyr3-octre otide might also be effective in patients refractory to conventional strategies.
Insights
Novel radiopharmaceuticals targeting somatostatin receptors show promise for diagnosing and treating neuroendocrine tumors. Receptor-targeted radiotherapy offers a potentially cost-effective and effective treatment option, even for patients resistant to conventional therapies.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmacy
Background:
- Malignant neuroendocrine cells frequently express somatostatin receptors (SSTRs 1-5).
- Targeting these SSTRs offers diagnostic and therapeutic opportunities for neuroendocrine tumors.
- Radiolabeled peptide ligands for SSTRs are established in clinical diagnostics and show therapeutic potential.
Purpose of the Study:
- To evaluate the diagnostic and therapeutic efficacy of novel somatostatin receptor-targeted radiopharmaceuticals.
- To compare the diagnostic performance of different radiotracers for neuroendocrine tumor imaging.
- To assess the clinical potential of radionuclide receptor-targeted radiotherapy.
Main Methods:
- In vitro studies demonstrating SSTR expression on neuroendocrine tumor cells.
- Clinical application of SSTR scintigraphy using 111In-DOTA-lanreotide in 166 patients.
- Comparative analysis of scintigraphic results with 111In-DTPA-DPhe1-octreotide and 111In-DOTA-DPhe1-Tyr3-octreotide.
- Evaluation of initial results with 90Y-DOTA-lanreotide and 90Y-DOTA-DPhe1-Tyr3-octreotide for radiotherapy.
Main Results:
- 111In-DOTA-lanreotide scintigraphy yielded positive results in 93% of patients.
- Discrepancies in tumor uptake and lesion detection were observed in approximately one-third of patients when comparing different tracers.
- Initial data suggest significant clinical potential for 90Y-labeled DOTA-peptides in receptor-targeted radiotherapy.
Conclusions:
- Somatostatin receptor scintigraphy is a valuable tool for diagnosing and monitoring neuroendocrine tumors.
- Novel radiopharmaceuticals like 111In/90Y-DOTA-lanreotide and 111In/90Y-DOTA-DPhe1-Tyr3-octreotide show promise for improved diagnosis and treatment.
- Receptor-targeted radionuclide therapy offers a potentially cost-effective and effective treatment strategy, including for refractory cases.